Current Report Filing (8-k)
August 01 2018 - 9:16AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported): August 1, 2018
OWC
PHARMACEUTICAL RESEARCH CORP.
(Exact Name of Registrant as Specified in its Charter)
Commission
File No.: 0-54856
Delaware
|
|
98-0573566
|
(State
of Incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
2
Ben Gurion Street, Ramat Gan, Israel
|
|
5257334
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
Telephone Number, including area code: +972-72-260-8004
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 Other Events.
OWC
Pharmaceutical Research Corp. (“OWC”) a developer of cannabinoid-based therapies targeting a variety of different
medical conditions and disorders through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., announces the initiation
of the final stage of its Phase I, placebo controlled, maximal dose study (the "Psoriasis Study") to determine the safety
and tolerability of topical ointment containing medical grade cannabis in healthy volunteers. On June 28, 2018, the Company announced
that it had successfully completed the initial stage of this trial, which comprised the single dosing of healthy volunteers. The
final stage of the trial comprises the twice daily dosing of healthy volunteers for 6 weeks.
The
study is being performed by Professor Aviv Barzilai, Director of the Department of Dermatology at Chaim Sheba Medical Center.
Sheba is a university-affiliated hospital that serves as Israel's national medical center and is one of the leading integrated
medical centers in the Middle East.
Mr.
Mordechai Bignitz, the Chief Executive Officer of OWC stated: “We mentioned in our recent letter to shareholders that we
were waiting for licenses in order to initiate this trial. This approval has now been obtained and we will immediately initiate
clinical testing. Validation of safe and efficacious therapeutics is key to our mission and we aim to progress our studies as
rapidly as possible, adhering to best clinical practices”.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
OWC
Pharmaceutical Research Corp.
|
|
|
|
|
By:
|
/s/
Mordechai Bignitz
|
|
Name:
|
Mordechai
Bignitz
|
|
Title:
|
Chief
Executive Officer
|
Date:
August 1, 2018
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Sep 2024 to Oct 2024
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Oct 2023 to Oct 2024